Skip to Content

Pacritinib (Vonjo®) in Cytopenic Myelofibrosis

Download PQI pdf 0.22MB

Last Updated: May 31, 2024

By: Sarah Rockwell, PharmD, BCOP

About this PQI

The purpose of this PQI is to discuss clinical considerations and adverse effect management surrounding the use of pacritinib (Vonjo®) in myelofibrosis (MF) and thrombocytopenia.

More About This PQI

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI